Home / Pharma news / Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile

Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for CDI and who are at high risk for CDI recurrence. Zinplava is not an antibacterial and does not treat an active CDI infection. Zinplava is a human monoclonal antibody that binds with C. difficile toxin B to prevent its effects on human cells. Common adverse reactions include nausea, pyrexia and headache. Heart failure, a serious adverse reaction, was noted in 2.3% of Zinplava-treated patients and 1.0% of placebo-treated patients.

 

Read more @ http://apintuslabs.com/

Check Also

Diabetes-Silent Killer

The total estimated cost of diagnosed diabetes in 2017 was $327 billion, including $237 billion ...

%d bloggers like this: